EarlyCDT®-Lung is a simple blood test which is ordered by your Doctor to aid in the risk assessment and early detection of lung cancer.
Early in the development of a solid tumour cancer, the body mounts an immune response to certain by-products, or proteins, (tumour antigens) from cancer cells by producing autoantibodies. These autoantobodies which can rise in the earliest stages of cancer, and have been shown to be present at all stages, are produced in sufficient quantities to be measured in an individual's blood using a simple blood test, EarlyCDT-Lung.
There is no one type of tumour associated antigen or autoantibody that can be used to detect all or any type of cancer, therefore EarlyCDT-Lung has been developed to measure a panel of 7 autoantobodies associated specifically with lung cancer.
EarlyCDT-Lung has been developed so that individuals at moderate or high risk of developing lung cancer can benefit from an increasing chance that lung cancer can be detected at the earliest possible stages, when treatment can be most successful.
The EarlyCDT-Lung test can also be used in conjunction with diagnostic imaging such as x-ray or CT scan, to further assess the risk of lung cancer being present where indeterminate lung nodules have been detected but which may or may not be a sign of cancer.
This is not a genetic test for predisposition—a positive test may indicate the presence of the disease and an increased risk of malignancy. The test is sent to and performed in Oncimmune’s CLIA-certified laboratory in Kansas City, USA. Currently, EarlyCDT-Lung is in use by more than 2000 physicians across the United States, and has aided in the detection of numerous early stage lung cancers, and is now available in the UK.
Watch a five-minute introductory video on EarlyCDT-Lung.